Venture Capital in Life Sciences (III): Monoclonal Antibodies in the Treatment of Ankylosing Spondylitis
The Use of Monoclonal Antibody Drugs as Treatment for Anklylosing Spondylitis The application of monoclonal antibody drugs is a relatively new innovation. Approximately 54% of
Some of Silicon Valley’s best and brightest brains have invested their money in an artificial intelligence startup named Vicarious. Among these brains include Facebook founders
Over the past decade, the genomics revolution has led to the emergence of numerous groundbreaking personalized medicine as well as multiple diagnostic and therapeutic targets.
Remember when everyone thought Facebook was crazy for trying to acquire Snapchat for $3 billion? Well, news has just come out that Facebook bought Snapchat’s
Uber has started this new year with a lot of bad publicity. First, Uber received a lot of backlash for their price surges due to
While starting your own business from bottom up can be thrilling, startups need to manage their cash wisely or risk losing their investments. Having sufficient
Didn’t Expect to be The Winner of the San Diego Business Journal’s Innovation Awards Back in November 2012, I was excited from all the good
As a start-up, you know that sometimes project planning can be a challenge. You might have a general idea of what your group is trying
Our intrepid leader, Alexander Wallin, contributed an article today on Seeking Alpha that will give beginning investors a primer on the array of crowdfunding options
Today marks the soft launch of our new beta. We’ve been working tirelessly to create the first authentic social investing platform and we’re almost finished.
Crowdfunding gives you the chance to invest early, before angels and VCs. (Photo Credit: Venture Beat) As our readers have probably realized, we’re excited about
The financial services industry has gone too long without accountability. Plenty can be written about the macro effects of the financial crisis — out of
Private financing hasn’t been easy for small- to mid-sized companies the past 10 years. Ever since Enron and Sarbanes-Oxley (SOX), regulations and associated fees have